Alnylam posts 150% growth in TTR franchise, maintains $4.4B-$4.7B revenue outlook for 2026

Alnylam Pharmaceuticals reported a strong 150% year-over-year growth in its TTR amyloidosis franchise in Q1 2026 despite challenges from insurance and pricing pressures. The drug Amvuttra is gaining market share as a front-line treatment. The company maintains its full-year revenue guidance of $4.4 billion to $4.7 billion and is investing in earlier diagnosis and care coordination to grow its market. Upcoming updates on early-stage treatments for bleeding disorders, Huntington's disease, and obesity could attract further investor interest, although major clinical catalysts may be delayed.